
Arrowhead Pharmaceuticals ARWR
$ 70.74
2.34%
Annual report 2025
added 11-25-2025
Arrowhead Pharmaceuticals Interest Expense 2011-2026 | ARWR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.26 M | -1.75 M | 1.54 M | 765 K | 2.07 M | -583 K | - | 7.49 K | 1.31 M | 57.4 K | 418 K | 82.1 K | -998 K | 36 K | 86.5 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.26 M | -1.75 M | 593 K |
Quarterly Interest Expense Arrowhead Pharmaceuticals
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 K | 341 K | - | 760 K | 7.24 M | 421 K | - | 306 K | 5.06 M | 2.85 M | - | - | 1.76 M | -707 K | - | 664 K | -110 K | 1.15 M | - | - | 1.15 M | - | - | - | - | - | - | - | - | - | 1.31 M | 1.31 M | 5.72 K | 1.31 M | - | - | 1.31 M | - | 483 K | 483 K | 536 K | -53.2 K | 81.3 K | 10.1 K | -53.2 K | -5.33 K | -998 K | 259 K | -5.33 K | 22.7 K | 27.3 K | 14.4 K | 7.42 K | 7.88 K | 70.8 K | 20.5 K | 7.88 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.24 M | -998 K | 707 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
ANI Pharmaceuticals
ANIP
|
-4.03 M | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Adagene
ADAG
|
1.11 M | $ 2.75 | -5.5 % | $ 155 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.17 | -2.76 % | $ 7.63 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Biogen
BIIB
|
250 M | $ 178.24 | 1.2 % | $ 26 B | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 225.36 | 0.63 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
CASI Pharmaceuticals
CASI
|
2.9 K | $ 0.99 | -0.01 % | $ 135 M | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Biosciences
CBIO
|
1.04 M | $ 9.63 | -5.08 % | $ 634 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 4.05 | -1.22 % | $ 8.81 B | ||
|
Amneal Pharmaceuticals
AMRX
|
11.8 M | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Cerus Corporation
CERS
|
1.98 M | $ 2.32 | -0.22 % | $ 428 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M |